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Pathology of human renal cystic disease
There are several pathologic conditions in humans which
result in tubulocystic enlargement in the kidney [1, 2]. In some
cases, renal cystic development is genetically determined and
maybe the primary disease event (Table 1). The most common
example is autosomal dominant polycystic kidney disease
(ADPKD) which is estimated to afflict 1 in 1000 live births [3].
Autosomal recessive polycystic kidney disease (RPKD) occurs
less frequently (1 in 100,000 live births), but is more aggressive
in its course since it is usually lethal to infants within their first
year. Another significant inherited condition leading to renal
tubule cyst formation is the nephronophthisis-medullary cystic
disease complex, which has been described as an autosomal
recessive trait in the juvenile form and autosomal dominant in
the adult form of disease. Tubulocystic enlargement may also
occur sporadically in association with hereditary syndromes,
such as von-Hippel Lindau disease and tuberous sclerosis. In
yet other cases, renal tubule cysts may develop in small or large
numbers in response to non-genetic factors. For instance,
simple cysts occur with increasing frequency with advancing
age, but rarely compromise renal function. By contrast, ac-
quired renal cystic disease, which affects approximately 40% of
non-ADPKD patients receiving hemodialysis for end-stage re-
nal failure, may result in the development of multiple cysts [4].
Additional reports have described renal cysts after long-term
administration of lithium chloride [5] and exposure to diphenyl-
amine [6].
A renal tubule cyst is defined as a segment of the nephron
enlarged to a diameter of 200 microns or more, and consists of
a fluid-filled, distended sac lined by a single layer of epithelium.
It would seem from the pattern of occurrence in humans and
from experimental studies in animals and tissue culture, that
renal tubule cysts can form in response to genetic, non-genetic
and toxic influences. Although there is a common end prod-
uct—a tubulocystic epithelium lining a fluid-filled expanded
lumen—it maybe spurious to consider that the mechanism(s) of
cyst formation are necessarily identical in all cases. Conceptu-
ally, it seems more likely that several pathogenetic pathways
converge on a single means of phenotypic expression. The
following discussion will center on what little is known about
the cell biology and underlying mechanisms governing cyst
formation in human genetic polycystic kidney diseases
(ADPKD, RPKD), but will draw occasionally on results ob-
tained from some appropriate experimental models (Table 2),
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when parallels or contrasts have bearing on studies in human
tissues.
RPKD is a rare but lethal form of polycystic kidney disease.
It occurs with an estimated frequency of 1 in 10,000 and
typically children are born with enlarged, malfunctioning, mul-
ticystic kidneys. For these reasons, this form of disease has
been studied rarely, but recently a mutant mouse strain C57/6J
(cpk) has been characterized and shown to represent an excel-
lent animal model for this disease [7, 8]. This fortunate circum-
stance does not apply to the more common ADPKD, which
affects approximately 500,000 people in United States. No
known animal model has been characterized. This disease
typically shows a slow progression in which renal cysts increase
in number and size, gradually replacing normal renal tubule
mass and leading to renal insufficiency in the fourth decade of
life, although symptoms of reduced ability to concentrate the
urine and hypertension often precede loss of renal function [9,
10]. Classical, pioneering microdissection studies of ADPKD
kidneys in the early stages of development of the disease
showed that cysts can arise as focal dilations originating from
any proximal or distal segment of the nephron [11—13]. This was
later confirmed by discriminatory lectin staining patterns [14].
In addition, ion and pH analysis of cyst fluid aspirated from
ADPKD kidneys had shown wide variations and led to the
broad classification of two types of cysts, designated "proxi-
mal" and "distal" [15—171. Macroscopic examination of end-
stage ADPKD kidneys shows that cyst enlargement is asyn-
chronous and can reach enormous proportions. Cyst size
commonly ranges < 1 mm to > 10 cm. This contrasts with
RPKD where cysts derive exclusively from distal collecting
tubules, and cysts are smaller and more homogeneous in size.
The genes responsible for ADPKD and RPKD have not yet
been isolated, although a major ADPKD gene (ADPKD-1) is
known to be linked to a highly polymorphic marker on the short
arm of chromosome 16 [18]. However, it appears that in
approximately 10% of cases of ADPKD, the gene on chromo-
some 16 is not responsible, since families with inheritance of
ADPKD unlinked to the 3'HVR region of the a-globin locus
have now been found in United States and in Europe [19—21].
The apparent existence of a minimum of two alleles for ADPKD
has not only complicated certainty of diagnosis, but unfortu-
nately increases the complexity of the task of isolating and
characterizing this genetic defect at the molecular level. How-
ever, significant progress has been made by several laboratories
towards this goal.
Progress has also been made at the cellular level. Light and
electron microscopy of human ADPKD kidneys shows that
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Table 1. Renal tubular cystic disease
Disease entity Causative factors Reference
Autosomal dominant Genetic: gene 1, on [3, 18]
polycystic chromosome 16
kidney disease gene 2, unknown [191
(ADPKD)
Autosomal recessive Genetic: gene and [1]
polycystic kidney chromosome
disease (RPKD) unknown
Polycystic kidney Genetic: autosomal [1]
disease: medullary dominant
type
Juvenile Genetic: autosomal [11
nephronophthisis recessive
Acquired renal Dialysis, drugs [4, 5]
cystic disease
Simple cysts Advancing age [3]




Tuberous sclerosis Associated with [21
(Bouneville' s hereditary
disease) syndrome
Table 2. Experimental models of renal cystic disease
Tubule
Causative agent affected Species Reference
In Vivo
Genetic CT Cpk mouse [7, 81
Drugs: diphenyl CT Rat [321
thiazole
phenol II CT Rat [591
Corticoids CT Rat, rabbit, [168]
hamster
In Vitro
Metanephric PT Mouse [124]
organ culture,
hydrocortisone
Monolayer PT,TAL,CT Human [231
ADPKD
epithelia
Explant ADPKD PT,TAL,CT Human [281
epithelia
Monolayer RPKD CT Human [169]
epithelia
Monolayer RPKD CT Mouse [1701
epithelia
MDCK cell line in "Distal" Dog [1711
collagen gel
Abbreviations are: PT, proximal tubule; CT, collecting tubule; and
TAL, thick ascending limb of Henle's loop.
cysts are lined by a single layer of polarized epithelium, in
which rudimentary microvilli and intercellular tight junctions
line the apical cell surface at the lumenal aspect of the epithelial
sheet lining the cyst [22—24]. So few differentiated characteris-
tics of the original tubule segment remain that it is usually
impossible, in fixed tissue slices, to determine the derivation of
cysts based solely on morphological characteristics. Even at a
functional level, isolated cystic epithelia have such dramatically
altered levels of marker enzyme activities and diminished
responses to hormone induction that characterization is dif-
ficult. However, these types of studies have provided insight
into certain ADPKD-associated symptoms. For instance, the
lack of ability of arginine vasopressin (AVP) to stimulate
adenylate cyclase in cyst lining epithelia [23], would help to
explain the concentrating defect which occurs early in ADPKD
patients. The mechanism of this modification is not caused by a
complete inability to increase cAMP levels in ADPKD epithe-
ha, since forskolin and PGE2 generate a cAMP induction,
although this was < 50% of the normal response [23, 25, 26].
These observations suggest an additional pre-cAMP lesion at
the level of AVP-receptor interaction, and/or faulty transduc-
tion of the signal via modified interactions with membrane G
proteins which act as the link between hormone-stimulated
receptors and the catalytic subunit of adenylate cyclase. A
possible explanation of hypertension, another early symptom of
ADPKD patients, has been suggested by studies at the cellular
level. Using specific antibodies and tissue sections from 19
cases of ADPKD using specific antibodies, both an increase in
number and an abnormal localization of renin-containing cells
immunolocalization showed 50% of these cells were seen in the
thin attenuated blood vessels that supply the walls of cysts, and
others were seen in the intervening in fibrous tissue [27].
Models of renal cystic disease
The morphological characterization of cyst lining cells as
simple epithelia has been confirmed and is retained in tissue
culture, both in flat, two-dimensional monolayers grown on
dried collagen [23], and in three-dimensional explants embed-
ded in collagen gels [28, 29]. Although the ADPKD epithelial
cells contain relatively few organelles and are morphologically
less specialized than renal proximal tubules, thick ascending
limbs of Henle or collecting tubule cells in vivo or in vitro, they
remain polarized with apical tight junctions and microvilli
facing upward in the dish. ADPKD epithelial are similar to
normal microdissected human renal tubules in vitro [29], in
their requirement for type 1 collagen or some other matrix
protein to establish this polarity. To confirm the validity of
primary culture monolayers of microdissected human ADPKD
cysts as a model system, a series of comparative studies was
carried out in freshly isolated human cysts and confluent
cultures. Good correlations were seen between the levels of
marker enzyme activities and adenylate responsiveness to
hormones, which suggested the suitability of this primary
culture system as an in vitro model system for the analysis of
renal cyst formation. Since these ADPKD epithelia grow easily
and rapidly in culture and can be maintained in primary culture
for up to six weeks or passaged for up to 15 transfers, this
provides a practical, reliable and reproducible system for the
analysis of cellular alterations in ADPKD epithelia [23]. The
advantages of viable epithelial monolayers are numerous and
obvious, allowing for direct comparisons with similar epithelia
derived from normal renal proximal convoluted and straight
tubules (PCT, PST), cortical and medullary thick ascending
limbs of Henle's loop (cTAL, mTAL) and cortical and medul-
lary collecting tubules (CCT, MCT) [25]. This is by no means
the only model available for analysis of cyst formation, but is
one of the few employing human-derived epithelia. Some other
commonly used model systems are listed in Table 2. Evaluation
of every cellular model of cyst formation and its relevance to
the mechanisms underlying human cyst formation in ADPKD
and RPKD is beyond the scope of this review.
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Fig. 1. Electron micrograph of a cyst lining epithelial cell from an ADPKD kidney, undergoing mitosis. Note the absence of a nuclear membrane
and chromosome condensation. Organdies are distributed at the periphery. Fixation was 2.5% glutaraldehyde in 100 m sodium cacodylate buffer
containing 5% sucrose for 4 hours. x 3,360.
Theories of polycystic kidney disease
Over the years there have been several theories to explain the
derivation of renal cysts. Originally the obstruction theory was
favored [30]. This suggested that fluid accumulation was the
result of occlusion of the renal tubule at a point distal to the
glomerulus, and thus a build-up of pressure resulted in cyst
formation. This theory has now been discounted since measure-
ments of intracystic pressures are not sufficiently high to
account for tubular distension [31]. Also, it has been demon-
strated that the majority of cysts become isolated from their
nephron of origin as an early event and not late as thought
previously.
This theory gave way to one of increased compliance of the
cystic basement membrane. This still holds some sway as a
unifying concept which could explain the systemic nature of
cyst development in several organs of patients with ADPKD
[101. Major basement membrane alterations are seen in drug-
induced cyst formation in rats [321, in cultured human ADPKD
cells and in the later stages of dominant and recessive cystic
disease. However, measurements of compliance in acquired
and mouse ADPKD cysts were not consistent with increased
elasticity as the exclusive cause of cyst expansion [331.
This theory has now given way slightly to one favoring
hyperplasia. The presence of hyperplastic nodules in ADPKD
cysts was originally reported by Evan, Gardner and Bernstein
[34] and confirmed by others in ADPKD and cystic diseases
that predispose to malignant transformation, such as von-
Hippel Lindau disease [24]. Although the occurrence of hyper-
plastic nodules is not sufficiently frequent or extensive to
invoke obstruction as a universal course of cyst formation,
calculations of cell height and cyst size suggest that cell division
must occur during cyst enlargement [35]. This has been con-
firmed by detection of mitotic profiles in cyst lining epithelial of
ADPKD kidneys in vivo (Fig. 1). Mitotic figures have not been
seen in electron micrographs of normal human renal tubules.
To explain formation of cysts instead of solid tumors, there
must be an accompanying defect which results in fluid accumu-
lation, presumably by secretion [36], since cysts have been
shown to close off from their nephron segment of origin early
after the onset of expansion. The ability of cysts to accumulate
fluid very rapidly has been confirmed in vivo by injection of
3H-water, the majority of which was detected in cyst fluids after
five hours [371.
It can be concluded that whichever defective gene product is
responsible for ADPKD or RPKD, the two basic criteria
necessary for cyst formation to occur are increased epithelial
S
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cell proliferation and altered fluid and transport. Alterations in
the proliferative potential of epithelia can be the result of:
modified epithelial/stromal interactions; altered susceptibilities
or synthesis of peptide growth factors; or abnormal expression
of growth related genes including protooncogenes. Renal fluid
transport is directed by electrochemical ion gradients estab-
lished by the sodium pump and normally results in reabsorp-
tion. Fluid accumulation in renal cysts could therefore be the
result of alterations in ion pumping or reflect alterations of
polarity of cell structure and/or function. Evidence for each of
these alterations will be considered.
The proliferative defect in tubulocystic epithelia
Matrix alterations
Stromal-epithelial interactions are of central importance in
the patterning of growth and differentiation in the developing
kidney [381. Although the precise mechanisms involved are not
fully understood, it is clear that the dynamic composition of the
extracellular matrix is responsible, at least in part, for control of
all normal epithelial cell migration, spatial organization, prolif-
eration and differentiation. It is therefore not surprising that
basement membrane defects are commonly found in diseases
associated with loss of normal cell division, including human
tumors of the breast [391, ovary [401, and in chemical carcino-
gen-induced rat mammary tumors [411. The structural defects
described include thinning, attenuation, layering and thickening
of the basement membrane. Similar descriptions have been
reported for the basement alterations seen surrounding the
renal medullary cysts of nephronophthisis [42], in pathological
specimens of human ADPKD [23, 43, 441, and in diphenyithia-
zole-induced renal cystic disease in rats [45]. Thickening has
also been described in renal aging and in diabetes [461.
In the kidney, as in all organs, the basement membrane
separates epithelia from the underlying interstitium and serves
several functions, including cell adhesion, tensile strength and
permselectivity. Normal renal tubule basement membranes are
made up of type IV collagen, and the non-collagenous glyco-
proteins laminin, entactin and heparan sulfate proteoglycans
[reviewed in 47]. The interstitial components include types I, III
and V collagen [48] and their relative abundance is develop-
mentally regulated in the kidney [48, 49]. Morphological alter-
ations in basement membranes in renal cysts could derive from
alterations in any of these extracellular matrix components and
could reflect defects in synthesis, post-translational modifica-
tions, secretion, extracellular assembly or degradation. Studies
of the structural component of type IV collagen, and laminin B I
and B2 chains which influence adhesion, growth and differen-
tiation in cpk mice, showed that steady state levels of mRNAs
were altered with the progression of RPKD. There was, how-
ever, no correlation between gene expression as determined by
Northern blot analysis and protein expression as measured by
immunofluorescence, since basement membrane staining be-
came weaker and mRNA levels increased in endstage kidneys
[50]. Our own findings have also shown that human ADPKD
epithelia continue to synthesize immunoreactive laminin and
type IV collagen in vitro and in vivo [43, 44]. It is also of interest
that steady state levels of type IV collagen mRNAs increased
significantly in ADPKD, but not markedly until the final stages
of disease progression (Fig. 2, courtesy of Dr. J.T. Norman,
Fig. 2. Northern blot of total RNA probed with 32P-cDNA for type IV
collagen, (HT2I, Dr. D. Prockop, Jefferson, PA). Lanes 1 and 2,
normal adult kidney; lanes 3 and 4 early stage ADPKD; lanes 5, 6, 7 and
8 end-stage ADPKD kidney. Note increase in steady state levels of type
IV collagen mRNA, particularly in end-stage kidneys. Courtesy of Dr.
iT. Norman, UCLA Division of Nephrology.
UCLA). Thus, alterations in the structural component of cystic
basement membranes may occur, but that as a late event is
unlikely to be a primary change initiating cyst enlargement. No
changes were found in type I collagen, laminin B 1 mRNA, or
protein expression.
More dramatic alterations were seen in the heparan sulfate
proteoglycan (HSPG) component of cystic basement mem-
branes. This integral component of the basement membrane
consists of a core protein with glycosaminoglycan (GAG) side
chains. These molecules can vary considerably in size in a
tissue specific fashion [5 1—53] but are thought to belong to a
single gene family. Proteoglycans have been assigned roles in
cell adhes4on [54], interstitial collagen and fibronectin binding
[551, and cell proliferation [56—58]. In several cell systems
proteoglycans have been shown to inhibit cell proliferation. In
this context it maybe important to note that both in drug-
induced cystic development and in human ADPKD cultured
epithelia, reduced structural integrity of the heparan sulfate
proteoglycan component of basement membranes has been
reported [23, 45], and in both conditions this was associated
with increased epithelial cell proliferation [23, 43, 44, 59].
Despite a rapid incorporation of H2[35S04] into human ADPKD
monolayers, no complete basement membrane structure was
synthesized. Instead, ruthenium red positive spheroids were
secreted on the basal surfaces of confluent monolayers. Immu-
noprecipitation studies in normal and ADPKD cultures in which
short-term labelling with 35S-methionine was used as an index
of core protein synthesis, no differences were found (Fig. 3,
courtesy Dr. J. Hassell, Pittsburgh). This suggests that alter-
ations in HSPG synthesis does not occur at the level of protein
precursor synthesis, but rather at a later step when sulfated side
chains (GAG) are inserted into the core protein. It remains to be
determined whether the structural abnormality of ADPKD
basement membrane HSPG is due to inappropriate post-trans-
lational processing or to differential degradation, presumably
controlled by the action of extracellular proteases [60]. Thus, it
is possible to speculate that a reduction in the integrity of the
normal spatial deposition of FISPG in the basement membranes
of cystic epithelia could result in some loss of inhibition of cell
proliferation.
Cell growth is under the control of several interactive intra-
cellular and extracellular factors. An abnormality in cell growth
control, such as the limited hyperplasia seen in cyst formation,
could be the result of abnormalities at any of these levels of
control. Extracellular controlling factors fall into two catego-
ries: insoluble and soluble. The former includes extracellular
matrix proteins as discussed above and the latter includes
peptide growth factors.
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Fig. 3. Autoradiogram of
immunoprecipitation of laminin A and B
chains (lane b) and HSPG core protein (lane
c) in confluent cultures of normal proximal
tubule (N) and ADPKD (P) epithelia. Cells
were labelled with 35S-methionine (1 mCi/mi)
for 1 hour at 37°C. Lane a shows control
samples incubated with pre-immune serum.
Courtesy of Dr. J. Hassell, University of
Pittsburgh, School of Medicine.
Growth factor abnormalities
Orderly cell division depends on an exquisite coordination of
events that regulate the cell cycle during which cells progress
from one mitosis to the next. During this cycle, cells initiated by
a mitogenic stimulus pass through: a quiescent phase (G1),
during which RNA and protein synthesis take place; followed
by S phase, during which DNA synthesis takes place; and after
DNA replication has stopped, into G2 phase which culminates
in mitosis [61]. In the normal kidney, rapid cycling of prolifer-
ating cells takes place during certain specific stages of fetal
organogenesis, but after epithelial cell differentiation into highly
segmented nephron units is complete, division stops and cells
remain in the prereplicative (G0) state. Thus, in normal adult
kidneys, the mitotic index in renal tubules is very low (0.1%),
reflecting the very low level of cell renewal. Renal tubule cells
are not, however, irrevocably "terminally" differentiated,
since they can be stimulated to re-enter the cell cycle and
complete several rounds of cell division in response to injury in
vivo or by the addition of serum or specific growth factors in
vitro [62—64].
Several factors act in concert to control epithelial cell prolif-
eration including: interactions with specific extracellular matrix
proteins [65]; the mitogenic influence of cell type specific
soluble growth factors; and the expression of cell cycle regu-
lated genes [reviewed in 661. Certain growth factors are known
to act at specific stages of the cell cycle. For instance, platelet-
derived growth factor (PDGF) and fibroblast growth factor
(FGF) exert mitogenic effects on cells early in the cell cycle, at
the G0/G1 interface, and are thus termed competence factors.
"Entry" factors, such as epidermal growth factor (EGF) and
insulin act early in G1. Progression factors act later in G1 and
include insulin-like growth factors (IGF-1, IGF-2) and glücocor-
ticoids [67]. Switches in and out of G1 are thought to be the
major determinants of post-embryonic cell proliferation, and
therefore, defective control would lead to conditions such as
hyperplasia.
Abnormal cell proliferation maybe the result of aberrant
expression of normal mitogenic pathways, the molecular medi-
ators of which are a family of peptide growth factors that
circulate in the blood or are released locally and interact with
target cells through specific receptors. These types of growth
factors have three potential modes of action: endocrine, in
which their action is analogous to that of hormones, in that
factors released from a distant site exert effects on different cell
types in a remote target tissue, after circulation; paracrine, in
which growth factors released from one cell type stimulate
proliferation of different cell types nearby, without involvement
of systemic circulation; and autocrine, in which growth factors
produced by one cell type have direct mitogenic effects on the
same cell [68]. Since a prerequisite for growth factor response is
occupancy of specific cell surface receptors, an increased
response to normal mitogenic regulators in cystic hyperplasia
could simply be the result of increased receptor number or
affinity. Alternatively, since many growth factor receptors
contain tyrosine kinase activity, alterations in phosphorylation
and/or alterations in cellular substrate may be crucial. After
binding to receptors, a cascade of events is initiated leading to
diverse early cellular responses including increased phosphati-
dylinositol turnover, expression of competence genes, activa-
tion of phospholipase A2, changes in cell shape and ion changes
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[69]. The relationship between these alterations and the later
event of stimulation of DNA synthesis is unclear.
Normal renal tubule epithelia possess receptors for a wide
variety of growth factors and the kidney is itself, a rich source
for several growth factors [70]. Therefore, it is possible that in
the hyperplasia underlying cyst formation, there might be
inappropriate growth factor and/or growth factor receptor
expression in the affected epithelia. Under normal conditions in
the kidney, there is a balance between mitogenic and inhibitory
growth factors, which presumably normally favors inhibition
since so little cell renewal takes place. An overexpression of
mitogenic growth factors or loss of sensitivity to inhibitory
factors are therefore potential mechanisms underlying the inap-
propriately increased epithelial proliferation in renal cyst en-
largement.
Epidermal growth factor (EGF) is a 6.1 kD peptide, which
acts via interaction with a specific, high-affinity 170 kD receptor
which possesses intrinsic tyrosine kinase activity [71, 721.
Overexpression of EGF receptors has been demonstrated in
several human cancers and tumorigenic cell lines [73—76] and in
liver regeneration [77]. The normal adult kidney has been
shown to be a major source of EGF mRNA, although relatively
little peptide is stored there [78]. Immunoreactivity for EGF has
been detected in distal tubule cells including thick ascending
limbs, distal convoluted tubules, and medullary collecting tu-
bules and EGF receptors are paradoxically present on the
basolateral membranes of proximal tubule cells. The normal
role of EGF in the kidney is unclear at present, but it has been
clearly demonstrated as a potent mitogen for primary cultures
of rabbit proximal tubules and cortical collecting tubules [63,
79] and for the proximal and distal tubule-derived cell lines,
LLC-PK1 and MDCK [80, 81]. Since EGF had been detected in
human breast cyst fluid, although virtually undetectable in
plasma [82], we were prompted to examine the localization of
EGF and its receptor in ADPKD tissues and cultured cells. The
mitogenic action of EGF was significantly (5 1%) increased in
cultured ADPKD epithelial monolayers by comparison to age-
matched control cultures derived from human proximal tubules,
thick ascending limbs or collecting tubules. Examination of
immunoreactivity showed that not only cyst-lining epithelial
cells but also cyst fluids contained large amounts of immuno-
fluorescence. This was particularly marked in the small cysts in
the early stages of development of the disease [83, 84]. This
correlated with radioimmunoassay findings in which detectable
levels of EGF were found in ADPKD and von-Hippel Lindau
cyst fluid contents [851. In addition, EGF has been shown to
exert hyperplastic effects in cystic proximal tubules in mouse
metanephric organ culture [86]. This, therefore, suggests that
hypersensitivity to EGF can lead to the hyperplasia necessary
for cystic enlargement in the kidney. In ADPKD, EGF receptor
immunoreactivity has been demonstrated on apical as well as
basal cell surfaces of cyst lining epithelia, and specific binding
of '251-EGF was demonstrable both on the apical and basal
surfaces of ADPKD epithelia grown to confluence on perme-
able membrane supports. These results support the notion that
part of the hyperplastic response underlying increased cell
proliferation in cyst formation is an autocrine effect, since in
ADPKD, EGF is synthesized by the epithelia cells lining the
cysts, secreted apically into the cyst lumen, and is capable of
interacting with the same cells by virtue of apically located
receptors. It is also conceivable that these increased levels of
EGF are partially responsible for the inhibition of the hydrooso-
motic effects of AVP, as has been demonstrated experimentally
in rabbit CCT [871. It is also of note that EGF has been reported
to decrease sodium reabsorption [881, which may have some
impact on fluid accumulation. It would also be of interest to
examine the occurrence and effects of TGFa in cystic disease,
since this structural homolog of EGF is transiently synthesized
during fetal renal development and expression of the gene for
both TGFa and its receptor are frequently associated with
carcinomas [89].
The overall proliferative response of any cell type in vivo
reflects the effects of interactions between several growth
factors [90]. In the kidney, it is likely that TGF/3 interactions
would be important, since under normal conditions this is a
potent inhibitor of renal tubule proliferation. In fact, TGF2
was first isolated from a renal epithelial-derived cell line, BSC-l
[91]. TGF1 and 2 belong to the same gene family [92] and are
multifunctional growth factors which exert differential effects
according to the target cell type. They have been shown to be
mitogenic for cells of mesodermal origin, including fibroblasts,
but inhibit cell division of epithelia. In the normal kidney, as in
other organs, it has been shown that TGF/3 antagonizes the
mitogenic action of EGF, dexamethasone and insulin [83, 85,
93]. TGFf3 is a ubiquitous, 25 kD peptide [941 which interacts
with the equally ubiquitous membrane receptors [95]. Little is
known about the mechanism of TGFI3 receptors 1961, except
that they do not possess tyrosine kinase activity [971. A
disturbance in the normal balance between positive and nega-
tive growth regulators, such as TGF/3 could be responsible for
uncontrolled cell growth as has been demonstrated in human
breast tumor cells [98], retinoblastoma cells [991, and tumor-
promoter-stimulated mouse epidermis cells [1001. Our studies
on the effects of TGF on ADPKD epithelial proliferation in
vitro showed a marked loss of inhibitory activity of TGF/3 with
regard to EGF, dexamethasone and insulin mitogenesis [83, 84],
and, therefore, suggests a further potential mechanism for the
enhanced proliferation of ADPKD cyst lining epithelia. It
remains to be determined whether the alterations in TGF/3
sensitivity are due to a decreased number of receptors or
decreased proteolytic activation [101, 102].
Other growth factors relevant to renal development, includ-
ing IGF-l and 2 [103], have been tested for possible discrimi-
natory proliferative effects in cultures of human normal renal
tubule and ADPKD epithelia, but little difference has been
seen. It was of interest, however, that a significant proliferative
response to PDGF was found in ADPKD fibroblasts and that
immunoreactivity for this peptide was demonstrated in cyst
lining epithelia. This appears to be a case of abnormal paracrine
regulation of fibroblast proliferation exerted by tubulocystic
epithelia, and may correlate with findings that BSC-l cells
secrete a PDGF-like protein [1041. This may therefore have
relevance with regard to fibrosis, which is another characteris-
tic of ADPKD and medullary cystic kidneys.
Cell-cycle regulated gene expression
Little is known about the expression of cell-cycle regulated
genes in the kidney. During embryonic renal development the
N-myc proto-oncogene has been demonstrated by in situ hy-
bridization to be confined to differentiating epithelial cells [1051.
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In adult rabbits, during proliferative renal repair after acute
nephrotoxic injury, transient increases in steady-state mRNA
levels were seen: for the proto-oncogenes c-fos, c-myc and
c-Ha-ras; for the growth-regulated structural protein genes
vimentin and f3-actin; and for the transport protein genes
NaK-ATPase, ADP-ATP translocase and calcyclin [621. A
single study in the cpk mouse model of RPKD using similar
techniques has demonstrated an increase in c-myc proto-onco-
gene, but paradoxically this was not seen until late in the
progression of the disease [1061. This was a surprising finding,
since c-fos and c-myc are usually associated with proliferation
in the early stages. Further studies will be required to charac-
terize early response genes at stages of disease development
that correlate with the onset of proliferation. The involvement
of c-myc in renal cystic development is further implicated by
recent reports that transgenic mice with the c-myc gene develop
renal cysts and die prematurely of renal failure [107].
Fluid transport defects in renal cyst formation
Alterations in NaK-ATPase
NaK-ATPase is a ubiquitous, heterodimeric, integral mem-
brane protein responsible for establishing and maintaining the
electrochemical gradients for Na and K. In polarized epithe-
ha, such as renal tubules, NaK-ATPase enzyme complexes
are segregated in basolateral membranes only, consistent with
its function of vectorial active pumping of Na out of cells into
the blood. In light of its major reabsorptive function, it is not
surprising that the kidney is a rich source of NaK-ATPase.
Distribution is non-uniform along the nephron and the number
of pump units correlates with the hydrolytic activity of individ-
ual nephron segments, being maximal in thick ascending limbs
of Henle and distal convoluted tubules (5 x l0 enzyme U/cell),
high in proximal convoluted tubules, lower in proximal straight
tubules and collecting tubules, and barely detectable in thin
limbs of Henle's loop [108].
The NaK-ATPase enzyme complex is made up of two
dissimilar types of subunit (a and /3). The larger (100 kD) a
subunit is a polypeptide which spans the cell membrane at least
six times and is the catalytic moiety, bearing the phosphoryla-
tion-ATP and ouabain-binding sites. The smaller (55 kD) /3
subunit is a glycoprotein with a single membrane spanning
region and is essential for correct insertion of the enzyme
complex into the appropriate cell membrane [109, 110]. Each
subunit is synthesized separately as a product of distinct genes
on separate chromosomes. The a subunit is encoded by a highly
conserved multigene family and several isoforms have been
detected in various species, including three in humans, the
genes for which are located on different chromosomes (Table
3). The expression of these isoforms is developmentally regu-
lated [111, 112] and tissue dependent [109, 113, 114], the a
isoform predominating in the kidney [1151. Although biochem-
ical data concerning the existence of multiple isoforms of the /3
subunit are sparse, multiple mRNAs have been isolated in
sheep and rat [116], and Fambrough has demonstrated two
isoforms in chicken [1171. Thus, there is a complex pattern of
NaK-ATPase subunit isoform expression, and this can be
specifically and differentially modulated by sodium flux and
pressure changes [118, 1191. Like all proteins, NaK-ATPase
subunit precursors are synthesized on ribosomes, translocated




















into the endoplasmic reticulum and processed in the Golgi,
where maturation of the glycosylated /3 subunit involves con-
version of high mannose oligosaccharide side chains. It is
generally suggested that equimolar amounts of a and /3 subunit
form a2 132 complexes inserted into plasma membranes with
most of the a subunit on the intracellular side and most of the /3
subunit on the extracellular side. Tamkun and Fambrough [1201
have also shown that a significant proportion of NaK-
ATPase subunits may remain unassembled and intracellular,
and may present an additional means for rapid post-transla-
tional modification.
NaK-ATPase activity in the kidney can be increased
significantly by several means, including the steroid hormones
aldosterone [121, 122], thyroid hormone [123, 124] and triiodo-
thyronine [124], in remnant kidneys [125] and by increased
cellular Na concentration [1261. A significant finding by Avner
et al [124] showed that the induction of NaK-ATPase by
triiodothyronine in metanephric organ cultures was associated
with proximal tubule cyst formation. Subsequent studies have
shown that increased NaK-ATPase activity is also a consis-
tent property of RPKD in the cpk mouse [86] and in human
ADPKD tissues [23, 127—129]. Since NaK-ATPase is the
active sodium pump enzyme and sodium ions are the major
osmotic determinant in the kidney, it is not surprising that
increased NaK-ATPase would accompany conditions of
increased ion and fluid transport.
Membrane polarity defects
Normal renal tubule epithehia are highly polarized cells with a
different complement of proteins in their apical membranes
from that in their basolateral membranes [reviewed in 130, 131].
Apical tight junctions separate these two sets of proteins and
prevent them from intermixing within the lipid bilayer of the
plasma membrane [1321. Establishment of epithehial polarity in
the kidney occurs early in fetal development [131] and is under
the control of the laminin A chain [65]. Typically, renal tubule
epithelia apical brush border membranes are characterized by
the presence of sodium-coupled transporters, brush border and
coated pit-specific antigens, and ectoenzymes anchored by
covalent links to glcosyl-phosphatylinositol (GPI) including
alkaline phosphatase, y-glutamyl transpeptidase and renal
dipeptidase [133, 134]. Renal tubule basolateral membranes
contain receptors for basement membrane proteins, hormone
and growth factor receptors, the Cl/HC03 exchanger, and
the sodium pump enzyme NaK-ATPase.
A loss of membrane protein polarity would be catastrophic
for renal tubule function and can be induced experimentally in
monolayer cultures of renal epithelia by deprivation of extra-
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cellular calcium, or in vivo in rat kidney proximal tubules by
limited ischemic insult [131, 135]. In both cases a mixing of
membrane proteins was seen, including NaK•ATPase and
alkaline phosphatase, and this was consistent with a loss in the
integrity of tight junctions. After repair by restoration of normal
(mM) concentrations of calcium or restoration of blood flow,
newly synthesized proteins were correctly inserted into polar-
ized membranes.
The precise intracellular mechanisms by which Na K-
ATPase subunits are sorted and targeted to basolateral mem-
branes remains obscure, although a role for the expression of /3
subunit in directing the a chain to the membrane is clear. It is
not known, however, whether fatty acid acylations play a role
in targeting and docking proteins. Once in the membrane,
polarity of NaK-ATPase is maintained by interactions with
membrane-associated proteins which are linked to the actin
cytoskeleton [136]. It has also been proposed that a complex
interaction with soluble pools of these proteins (fodrin and
ankyrin) maybe involved in insoluble complex formation [1371.
A dramatic and consistent finding in 20 specimens of ADPKD
kidneys has been that, in cystic epithelia, all immunoreactivity
for the a subunit of NaK-ATPase was localized exclusively
on the apical cell membranes, lining the fluid-filled cyst lumens
[127—1291. This was shown to be a functionally competent
enzyme by cytochemical staining techniques, ouabain sensitiv-
ity and biochemical assays on isolated apical and basolateral
membrane vesicles [1291. This defect was seen very early in the
onset of tubule dilation in ADPKD kidneys which contained
some cystic and some normal regions. In those kidneys,
NaK-ATPase location in normal, non-dilated tubules was
exclusively basolateral [127]. ADPKD monolayers grown on
permeable membrane supports in which apical and basal media
compartments were separated showed apical membrane immu-
no- and enzyme cytochemical staining and vectorial of trans-
port of 22NaCI from basal to apical media which was inhibitable
by ouabain [129]. Thus, an early defect in cyst formation in
ADPKD was the reversal of polarized insertion of NaK-
ATPase into apical membranes with consequent redirection of
net Nat-transport from the serosa into the tubule lumen.
Similar apical NaKtATPase is found in the choroid plexus
where it is associated with the vectorial transport of sodium
from the plasma into the cerebrospinal fluid [138]. However, in
this case there is also a reversal of polarity of several other
membrane proteins, such as Na/H antiporter to the basal
surface and Ca2-ATPase in the apical membrane surface. This
is not the case in ADPKD epithelia where the Nat/H f antiport
remained apical, and the anion exchanger and basement mem-
brane proteins remained basal in location. A survey of several
polarized markers led to the conclusion that there was a specific
mislocation of NaK-ATPase to the apical membranes of
cystic epithelia, rather than a complete reversal of cell polarity.
This was confirmed morphologically by the presence of apical
tight junctions and rudimentary microvilli and basal laminin,
type IV collagen and HSPG immunostaining [127, 129]. An
additional example of apical NaK-ATPase has been seen in
association with four cases of human arachnoid cysts [139], and
may suggest this as a general mechanism associated with fluid
secretion.
It has been demonstrated directly, by infusion of 3H-water
into ADPKD patients, that ADPKD cyst walls are highly
permeable to water [37], since 80% of radioactive label had
accumulated in cyst fluids after five hours. This suggests that
ADPKD cell membranes are different from normal ascending
limbs of Henle which are impermeable to water, and to collect-
ing tubules which are impermeable in the absence of vasopres-
sin. Since vasopressin has no effect on ADPKD epithelia with
regard to increasing cAMP second messenger [23], it is unlikely
to have any effect on water permeability in cysts. Thus,
permeability to water could reflect a proximal tubule origin, or
conceptually more likely, an increase in membrane fluidity.
It seems that some general properties are characteristic of the
fluid expansion observed in cyst development, including in-
creased NaK-ATPase activity and reversal of vectorial fluid
transport from normal to apical cell surfaces. This capacity for
fluid secretion has also been demonstrated in experimentally-
derived MDCK cell cysts in collagen gels [140]. Another
general feature in MDCK and in metanephric organ culture was
that cyst formation could be inhibited by ouabain, further
confirming dependence on NaK-ATPase [141]. In ADPKD
epithelia in vitro, apically applied ouabain also inhibited
NaK-ATPase and 22NaC1 transport into the apical medium,
but basally applied ouabain had no effect, further confirming the
mislocation of NaK-ATPase to the apical membranes of
ADPKD epithelia [142].
Cytoskeletal alterations in renal cystic disease
The epithelial cell cytoskeleton is comprised of microfila-
ments (actin), microtubules (tubulins), and intermediate fila-
ments (cytokeratins) [reviewed in 143]. These structural pro-
teins confer cell-type specific size, shape, and motility.
Intermediate filament proteins are highly insoluble and are
thought to be present largely in filamentous form [144]. Micro-
filaments and microtubules, however, may exist in both soluble
and insoluble pools and thus contribute to the morphology of
the cell and to the viscoelastic properties of the cytoplasm
[144—146]. Since cellular morphology may change profoundly
with the growth and differentiation state of the cell, it is not
surprising that the nature of the cytoskeletal proteins expressed
in a cell together with their localization and associations with
binding proteins may change.
In polarized cells, microfilaments and intermediate filaments
are major components inserting into intercellular junctions, and
hence are essential for the maintenance of membrane polarity
[143, 147]. Actin is also a major component of the cortical
cytoskeleton, the filamentous web observed just beneath the
plasma membrane, and is particularly prominent in the terminal
web, at the apical aspect of epithelial cells with a brush border,
such as renal proximal tubules [147]. Actin appears to play a
role in anchoring integral membrane proteins, including en-
zymes and transporters, via interactions with ankyrin, fodrin
and related proteins [136, 137, 148, 149]. Cytokeratins share the
role of establishing intercellular junctions with microfilaments,
and recent experiments indicate that they may also bind ankyrin
or fodrin [144]. Convincing evidence implicates microtubules in
the transport of organelles and in the delivery of apical mem-
brane proteins to the correct domain [150—154].
The importance of the cytoskeleton in renal cyst formation is
just beginning to be explored. As discussed above, renal cyst
formation requires expansion of tubules by limited hyperplasia.
The observed defects in basement membranes in cystic epithe-
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lia might have impact on, or even be directed by the actin
cytoskeleton via intracellular-extracellular interactions [148,
149, 155]. Cells with a proliferative defect share some proper-
ties with the transformed phenotype of tumor cells including a
loss of specialized ultrastructure and aberrant basement mem-
brane attachments. A direct association between growth abnor-
malities and cytoskeletal properties in cystic epithelia remains
to be explored.
The role of microtubules in cell division is well characterized
while the function of microfilaments and intermediate filaments
is not so clearly understood. The expression of intermediate
filament protein genes is highly cell-type specific [144, 145].
Cytokeratins are the major intermediate filament proteins found
in epithelial cells while vimentin predominates in cells of
mesenchymal origin [144]. Although some renal epithelia are in
fact derived from embryonic mesoderm, fully differentiated
tubule cells express cytokeratins typical of their epithelial
nature [156—158]. It is of interest, however, that coexpression
rats treated with daunomycin showed coexpression of cytoker-
atins and vimentin in renal epithelia, which was correlated with
the degree of cystic expansion and proliferation [158]. How-
ever, coexpression of these proteins was also observed in
several other diseases and may represent a non-specific re-
sponse to tubule injury.
The actin cytoskeleton also responds to the growth state of
the cell. Expression of different isoforms of actin can be
induced in cells treated with tumor promoters, agents which
facilitate but cannot initiate neoplastic transformation [159].
Although actin isoform expression has not yet been character-
ized in renal development, a novel isoform is transiently ex-
pressed in intestinal epithelia from neonatal mice [160]. The
significance of multiple actin isoforms, which differ only by a
few amino acids [161], is not fully understood, but it could be
that different isoforms have different affinities for specific
binding proteins. Our studies have shown that actin is exces-
sively abundant in epithelia from ADPKD renal tissue [128,
162]. The altered actin content appears to result from a post-
translational change or a change in isoform expression, since
differences in mRNA levels for f3-actin in ADPKD cells cannot
account for the excessive amounts of actin observed [129].
mRNA levels for /3-actin have also been measured in recessive
PKD in cpk mice and no significant differences were detected
[50]. In addition to the increased abundance of actin protein in
ADPKD cells, immunoperoxidase and fluorescence studies
have shown colocalization with apical NaK-ATPase in cyst
lining epithelia. Visualization of ADPKD cyst epithelial actin
filaments with rhodamine-conjugated phalloidin also showed a
consistent codistribution with the calpactin II (lipocortin I), the
calcium-phospholipid actin binding protein [163]. In addition,
calpactin II is excessively abundant in ADPKD [162]. This
observation is of particular interest because calpactin II is also
a major substrate for the tyrosine kinase activity of the epider-
ma! growth factor receptor [1641. The phosphorylation of this
protein correlates with the activation of phospholipase A2 and
subsequent release of plasma membrane arachidonate [165,
166]. Our hypothesis is that the over-abundance of calpactin II
may be an amplification response to prolonged stimulation of
the EGF pathway in ADPKD epithelia, since EGF is a potent
mitogen for these cells and is present in large quantities in cyst
lining epithelia and cyst fluid of expanding cysts, as discussed
above.
The fluid accumulation defect in cystic epithelia, in which
altered targeting and/or anchoring of membrane transport pro-
teins appear to play a role, also implicate modifications in the
cytoskeleton. The importance of intact cytoskeletal elements in
normal cellular processes, including secretion, is clear. Thus,
there could be a fundamental role for cytoskeletal abnormalities
in the initiation or maintenance of tubulocystic disease in which
several cellular processes are perturbed.
As described above, Nelson et a! have shown that the
NaK-ATPase is anchored in the basolateral membrane of
cultured kidney cells (MDCK cells) to the actin cytoskeleton
via ankyrin and fodrin [136, 137]. Microtubules do not appear to
have a direct effect on the targeting or anchoring of basolateral
membrane proteins, but microtubular disruption by coichicine
and vinblastine has suggested their integrity is essential for
transport of apically destined proteins to the correct plasma
membrane domain [150—154], although the possibility that the
effects of these agents were due to perturbation of the Golgi
could not be ruled out. An analogous process appears to act in
the delivery of secretory vesicles to the apical surface of
polarized cells, and calpactin I has recently been implicated in
the fusion process required for regulated secretion events [167].
The possibility that apically-destined membrane proteins are
delivered via the same processes as secretory granules remains
to be established, Thus, it can be speculated that the specific
mistargeting of NaK-ATPase to the apical plasma membrane
in ADPKD cyst enlargement, might be the result of alterations
of interaction with those cytoskeletal proteins responsible for
NaK-ATPase intracellular targeting or anchoring. Alterna-
tive possibilities remain to be explored including: possible
modifications in fatty acid acylation targeting and anchoring;
altered Golgi processing of NaK-ATPase subunits; and al-
terations at the level of the gene NaK-ATPase a and /3
subunits.
Conclusions and perspectives
The evidence presented suggests that numerous cellular
changes can occur during the initiation and progression of renal
cystic diseases of genetic and non-genetic origin. At least two
basic criteria are necessary for cystic expansion of renal tu-
bules: aberrant epithelial cell proliferation and lumenal fluid
accumulation. Epithelial cell growth can be regulated by insol-
uble factors in the extracellular matrix and by soluble peptide
factors. Both mechanisms are implicated in renal cystic devel-
opment since abnormalities of heparan sulfate proteog!ycan
matrix deposition and decreased sensitivity to TGFI3 have been
demonstrated, thus potentially reducing inhibitory regulation of
epithelial proliferation. In addition, hypersensitivity to the
epithelial mitogen, EGF has been found in genetic polycystic
kidney disease, where it is thought to be an autocrine factor and
is associated with the presence of aberrant apical membrane
receptors and increased protein amounts of the intracellular
EGF receptor tyrosine kinase substrate, lipocortin. Increased
NaK-ATPase activity is also a common feature of renal
epithelial cysts of genetic and non-genetic origin and is associ-
ated with the observed fluid accumulation. In human autosomal
dominant polycystic kidney disease (ADPKD), a specific rever-
sal of polarity of NaK-ATPase location has been demon-
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strated in the apical membranes of cyst lining epithelia, and
shown to be responsible for basal to apical transport of Na and
can be inhibited by apically applied ouabain.
Little information is available concerning the sequence of
events necessary to result in the phenotypic expression of renal
tubule cysts. However, it is clear from studies on early stages of
development of RPKD in cpk mice and in ADPKD kidneys with
> 50% morphologically-normal renal tubules, that the enhanced
activity and reversed membrane polarity of NaK-ATPase is
an early event. The presence of immunoreactive EGF in the
fluid of small cysts in early stage ADPKD kidneys also suggest
autocrine EGF production might be an early modification. By
contrast, alterations in the type IV collagen components of
cystic basement membranes appear to be later events. The
proliferative and fluid transport defects appear to be coordi-
nated in cyst formation, and must be a different process from
the hyperplasia of tumor formation in which rapid uncontrolled
growth leads to solid cell masses. Nevertheless, complete
analysis of expression of growth related genes, including pro-
tooncogenes during cystic development, would be instructive.
It maybe speculated that one of the observed defects in cystic
epithelia could be a primary change to which all the other
manifestations are linked in a secondary fashion. For instance,
there are well documented relationships between the actin-
based cytoskeleton and NaK4-ATPase polarity [136, 137],
secretion [148—1521, matrix [153—155, 1681 and growth factor
receptor substrate interactions [1631. In addition, there is evi-
dence of tight interactions between matrix proteins and growth
factors [169—171], matrix and polarity [172—1731 and intracellu-
lar and extracellular Na ion contents and proliferation [174,
175]. Until more evidence has been collected in normal renal
tubule epithelia, however, the primary defect will remain elu-
sive. The sobering possibility must also be considered that none
of the changes documented to date is the underlying cause, but
merely reflect the effects of cystic enlargement. A search for
alterations at the fundamental levels of signal transduction and
transcription factors remains to be explored.
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